Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Galen Settles Estrostep, FemHRT Litigation, Barr Picks Up Loestrin In Deal

Executive Summary

A product licensing agreement between Galen and Barr will settle FemHRT and Estrostep patent litigation inherited by Galen from Pfizer

You may also be interested in...



Seasonale DTC Ads Will Help “Mainstream” Extended-Regimen OCs, Barr Says

Barr is hoping to "mainstream" the concept of extended-regimen oral contraceptives with a direct-to-consumer campaign for Seasonale

Seasonale DTC Ads Will Help “Mainstream” Extended-Regimen OCs, Barr Says

Barr is hoping to "mainstream" the concept of extended-regimen oral contraceptives with a direct-to-consumer campaign for Seasonale

Loestrin transaction gets further FTC scrutiny

FTC has requested additional information on Barr's proposed acquisition of rights to Galen's Loestrin oral contraceptive line (1"The Pink Sheet" Sept. 15, 2003, p. 37). Barr had hoped to close the deal by Feb. 1; the company is "unable to determine the impact" of FTC's request for additional information...

Related Content

UsernamePublicRestriction

Register

LL1134420

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel